Revive Therapeutics Announces Publication of Research Data With Bucillamine in COVID-19

Revive Therapeutics Ltd. recently announced the publication of a scientific article evaluating the impact of medication, including Bucillamine, on antibody response to SARS-CoV-2 mRNA vaccines in Japanese patients with rheumatic diseases.  The article, titled Antibody Response to SARS-CoV-2 mRNA Vaccines in Patients with Rheumatic Diseases in Japan: Interim Analysis of a Multicenter Cohort Study, is published in Modern Rheumatology and can be found here.

The article described that antibody levels were significantly lower in the groups treated with TNF inhibitor (TNFi) with methotrexate (MTX), abatacept, mycophenolate mofetil (MMF), MMF or mizoribine (MMF/MZR) combined with calcineurin inhibitor (CNI), and rituximab or cyclophosphamide (RTX/CPA) compared with those treated with sulfasalazine and/or Bucillamine or CNI (p<0.01). The newly published study further validates the potential of Bucillamine in the treatment course for COVID-19.

Bucillamine, an oral drug with anti-inflammatory and antiviral properties, is currently being evaluated in a Phase 3 clinical trial (NCT04504734) in patients with mild to moderate COVID-19. The company intends to seek US FDA Emergency Use Authorization.

“The potential of Bucillamine for COVID-19 is evident with its anti-inflammatory and antiviral properties and its potential use in patients who have taken SARS-CoV-2 mRNA vaccines,” said Michael Frank, CEO of Revive.

The company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 (SARS-2 Coronavirus) at this time.

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation. For more information, visit